RESUMEN
AIMS AND BACKGROUND: To compare 2 multifraction radiotherapy schedules in the palliation of painful bone metastases. METHODS AND STUDY DESIGN: We retrospectively analyzed clinical data of 105 patients with a total of 140 painful bone metastases who were treated with 20 Gy in 5 fractions or 30 Gy in 10 fractions. The primary tumors were breast (30%), lung (28%), and prostate (14%). The main sites of irradiation were spine (n = 79) and sacrum or pelvis (n = 39). Pain was graded by patients according to the pain numeric rating scale just before and 1 month after radiotherapy. Pain progression was defined as an increase ≥2 on pain scale after an initial response. RESULTS: The overall response rate at 1 month was 88.6%. Overall response rate was 89.6% in the 20-Gy arm and 87.3% in the 30-Gy arm (p = 0.669). The rate of complete response was statistically better in patients treated with 30 Gy (p = 0.019). The mean reduction in pain was 3.2 in the 20-Gy group and 3.6 in the 30-Gy group. Pain progression was 6.5% and 1.6%, respectively. The incidence of acute toxicity was statistically significantly higher in the 30-Gy arm (23.8%) than in the 20-Gy arm (2.6%) (p = 0.001). One pathologic fracture of the irradiated bone was observed in the 30-Gy arm. Two lesions, one in each group, were re-irradiated for pain recurrence. Pain progression was found in 6.5% of the irradiated lesions in the 20-Gy arm and in 1.6% in the 30-Gy arm. CONCLUSIONS: In our series, both regimens achieved high rate of pain relief, although the group treated with higher total dose reported better complete response rate. The 30-Gy arm had a significantly higher rate of acute toxicity.
Asunto(s)
Neoplasias Óseas/radioterapia , Neoplasias Óseas/secundario , Fraccionamiento de la Dosis de Radiación , Fracturas Espontáneas/complicaciones , Manejo del Dolor/métodos , Dolor/etiología , Cuidados Paliativos/métodos , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Óseas/complicaciones , Distribución de Chi-Cuadrado , Femenino , Fracturas Espontáneas/etiología , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Dosificación Radioterapéutica , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Malignant skin adnexal tumors are rare neoplasms which are derived from adnexal epithelial structures of the skin: hair follicle, or sebaceous, apocrine or eccrine glands. Among them, eccrine porocarcinoma is the most frequent, with an aggressive behavior compared to other more common forms of non-melanoma skin cancer. Only few reports describe the treatment of metastatic adnexal tumors, and there is no consensus about the better strategy of chemotherapy. Given the few cases and the absence of randomized clinical trials, it is important to collect clinical experiences on these tumors. Most of these adenocarcinomas are very aggressive and also chemoresistant, and only a targeted-therapy could have an impact on patient survival. Therefore, further studies on the biology of these diseases are necessary. The purpose of the present review is to discuss the treatment of malignant neoplasms of cutaneous adnexae and to suggest some future therapeutic options based on targeted-therapy.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias de Anexos y Apéndices de Piel/tratamiento farmacológico , Terapia Combinada , Humanos , Neoplasias de Anexos y Apéndices de Piel/diagnóstico , Neoplasias de Anexos y Apéndices de Piel/terapiaRESUMEN
Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption and are widely used in the treatment of bone metastases. Osteonecrosis of the jaw (ONJ) is the worst side-effect related to BP use. At our Center, we have implemented internal guidelines regarding the management of patients with bone metastases from solid tumors. Our analysis includes 200 patients affected by solid tumors with bone metastases who received zoledronic acid. They underwent a baseline mouth assessment to evaluate their dental conditions and to perform dental care; a dental follow-up was performed every six months. All patients received calcium and vitamin D daily. Dental examination and application of preventive measures led to a total reduction in ONJ in our patients treated with zoledronic acid. The keystone in management of ONJ is prevention, and the risk of developing ONJ during treatment with zoledronic acid is reduced by implementing preventive measures.